Get the Stockscreener App
7.21
2.56%
0.18
Pre-market:
7.24
0.03
+0.42%
Arcturus Therapeutics Holdings Inc stock is traded at $7.21, with a volume of 334.54K.
It is up +2.56% in the last 24 hours and down -16.07% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$7.03
Open:
$7.13
24h Volume:
334.54K
Relative Volume:
0.71
Market Cap:
$204.93M
Revenue:
$67.22M
Net Income/Loss:
$-65.78M
P/E Ratio:
-3.0209
EPS:
-2.3867
Net Cash Flow:
$-79.02M
1W Performance:
+7.77%
1M Performance:
-16.07%
6M Performance:
+6.03%
1Y Performance:
-40.90%
1-Day Range:
$7.09
$7.42
1-Week Range:
$6.70
$7.42
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.21 | 199.81M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | B. Riley Securities | Buy |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
mRNA drug maker Arcturus hits Jefferies 2026 healthcare stage in New York - Stock Titan
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - Moomoo
How (ARCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting - Traders Union
Arcturus Therapeutics Holdings Inc (NQ: ARCT - FinancialContent
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - MSN
ARCTURUS THERAPEUTICS HOLDINGS INC UPSWING STARTED | ARCT STOCK NEWS (VWpPDIK5Ud) - fathomjournal.org
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MSN Money - MSN
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call - GuruFocus
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Should I Buy - Intellectia AI
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline - Investing.com
Trading Systems Reacting to (ARCT) Volatility - Stock Traders Daily
ARCT: Advanced rare disease pipeline, reduced expenses, and strong cash position support 2026 milestones - TradingView
ARCT: Achieved key clinical milestones in rare disease mRNA programs with strong financial runway - TradingView
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff - Bitget
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline - TipRanks
Arcturus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances - ChartMill
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics (ARCT) CFO granted 100,000 stock options - Stock Titan
[Form 3] Arcturus Therapeutics Holdings Inc. Initial Statement of Beneficial Ownership - Stock Titan
Q1 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics (NASDAQ: ARCT) Q1 2026 hit by 93% revenue drop - Stock Titan
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revenue plunge and leadership change at Arcturus (NASDAQ: ARCT) - Stock Titan
ARK/ Cathie Wood report 2.95M shares in Arcturus (ARCT) - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Repor - GuruFocus
Arcturus Therapeutics Holdings Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78 - MSN
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May - PharmiWeb.com
Press Release: Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - 富途牛牛
Arcturus plans after-hours results and a 4:30 p.m. ET call May 7 - Stock Titan
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - marketscreener.com
How Arcturus Therapeutics Holdings Inc. (ARCT) Affects Rotational Strategy Timing - Stock Traders Daily
ARCT Price Today: Arcturus Therapeutics Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Arcturus (NASDAQ: ARCT) schedules 2026 virtual meeting on pay, board and auditor - Stock Titan
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):